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Background: Acute eosinophilic pneumonia (AEP) is a rare febrile illness which is characterized by respiratory failure
and often requires mechanical ventilation. The causes and sequence of events of this disease at a biochemical and
histological level remain largely unknown. In this article we report the exceptional case, possibly unique, of a patient
who developed AEP and three pneumothoraces within less than one month during her hospitalization.
Case presentation: A 39-year-old German woman was admitted to our hospital for a laparoscopy-assisted vaginal
hysterectomy under general anaesthesia. The surgical intervention was followed by peritonitis in the early postoperative
course. Following anaesthesia induction with propofol/midazolam and during the prolonged therapy with several
broad-spectrum antibiotics, she developed AEP and three spontaneous (one left-sided and two right-sided)
pneumothoraces, the latter ones observed in quick succession. Symptoms, laboratory markers, and chest radiology
significantly improved after a one-day treatment with methylprednisolone.
Conclusions: On the whole, these pathological occurrences, together with similar cases reported in literature, can
support the conclusion of possible predisposing genetic factors at the lung tissue level of AEP patients, a view that
might shed new light on the pathogenesis of this disease. To provide a coherent pattern that explains the reported
evidence for AEP and pneumothoraces, independently from the causative stimulus, the supposed molecular mutations
could be localized in the connective tissue rather than in the epithelial cells. In order to interpret clinical and laboratory
evidence, as well as to support the main conclusions, the important part of scientific research here presented can also
assist physicians in making more informed decisions for the treatment of patients with pulmonary infiltrates.
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Acute eosinophilic pneumonia (AEP) is a febrile illness
leading to progressive, usually noninfectious respiratory
failure that is characterized by diffuse pulmonary infiltrates
with an increased number of eosinophils (> 25% of the
total cell count) in the bronco-alveolar lavage (BAL)
fluid, prompt response to corticosteroid administration,
and absence of any relapse after recovery [1]. The AEP
caused by drugs or toxins (drug-induced AEP) exhibits
clinical, radiographic and histopathological features that
are similar to the corresponding disease of unknown
etiology (idiopathic AEP), often making the distinction
between these two pathological entities difficult or* Correspondence: amiconisi@gmx.de
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article, unless otherwise stated.ambiguous. The most common therapeutic substances
that are suspected of causing drug-induced AEP are
antibiotics and non-steroidal anti-inflammatory drugs
[2]. Patients with idiopathic AEP frequently demonstrate
recent changes in smoking habits (not only initiation of
tobacco use, but also relapse after smoking cessation,
increased daily smoking frequency or quantity, and short-
term periods of passive smoking) [3].
Individuals who develop eosinophilic pneumonia may
have underlying and undiscovered predispositions, because
every day tens of thousands or even hundreds of thousands
people are exposed to substances (medications or toxic
products) or generic events (such as surgery, shock or
sepsis) reported in association with AEP [4-6]. Altogether,
only a small percentage of these exposed individuals ever
becomes ill; indeed, AEP is an infrequent disease with only
approximately 200 idiopathic cases reported worldwide
since it was first described in 1989 [1]. This theory of thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and the environmental (e.g., air-borne dust), external (e.g.,
drugs) or internal (e.g., biological mediators) stimuli has
already been postulated for other lung disorders [7].
In line with this point of view, it has recently been
described [8] the case of a Japanese girl of non-consan-
guineous family suffering from AEP and presenting loss-
of-function mutations in a gene (DOCK8) located on
chromosome 9. Other cases with eosinophilic lung
diseases have also been observed in the absence of
DOCK8 protein in lymphocytes [9]. Since patients with
DOCK8 deficiency present defective T cell function,
impaired production of antigen-specific antibodies and
a severe defect in interstitial dendritic cell migration
during immune responses with recurrent pulmonary
infections, these reports suggest that AEP represents
several pathophysiological processes that can fully and
rightly be estimated only by understanding both the
genetic and environmental contributions to its etiology
and pathogenesis.
The eosinophil plays a key role (even though not fully
understood) in the pathogenesis and clinical symptom-
atology of AEP. Blood eosinophilia is usually absent at
the disease presentation [1], suggesting that the initial
pathological stimulus originates at alveolar or pleural level.
Both basic and applied research studies have demon-
strated [10] that the selective activation of eosinophils
is induced by several mediators, all of them sometimes
categorized for simplicity with the most relevant of
which, interleukin-5 (IL-5), i.e. with the name of the
cytokine that exhibits the most specific and critical
control of eosinophilic functions, including the regulation
of eosinophilopoiesis in the bone marrow, the recruitment
of these granulocytes to tissues, the lengthening of their
survival by inhibiting apoptosis, and the differential
activation and release of toxic products through their
degranulation [11]. The local secretion of IL-5 and its
enhanced concentration within restricted regions, detected
in the broncho-alveolar lavage (BAL) fluid of patients with
AEP, apparently reflects the presence of eosinophil-rich
exudates in the alveoli andpleural cavity [12]. By contrast,
IL-5 is usually undetectable in serum of patients who
have AEP or eosinophilic pleural effusions, and IL-5
concentration decreases in BAL fluid after the resolution
of symptoms [13]. These data suggest that the accumula-
tion of eosinophils in the alveolar or pleural space is
mainly governed by the local concentration of IL-5,
the overexpression of which may be stimulated in the
genetically hypersensitive tissue of predisposed subjects
by an offending external/environmental factor [14].
We report the case of a non-smoking woman who, fol-
lowing a laparoscopy-assisted hysterectomy complicated
by peritonitis, developed AEP and pneumothoraces after
sedation with propofol and prolonged therapy withseveral broad-spectrum antibiotics. Observational evi-
dence and plausible reasoning supporting a possible
genetic predisposition to eosinophilic pneumonia is
offered.
Case presentation
A 39-year-old woman was admitted to our hospital for a
laparoscopy-assisted vaginal hysterectomy under general
anaesthesia (induced with midazolam, fentanyl and propofol,
and maintained with sevoflurane in oxygen/air mixture).
The patient reported an unremarkable medical and family
history and stated that she had never smoked. She also
denied the following: (a) regular exposure to environmen-
tal tobacco smoke (at home or at her workplace), (b)
abuse of illicit or recreational drugs, (c) food or medication
allergies, (d) recent camping or wild animal contact. A
more detailed history revealed that the patient was
otherwise healthy and had taken no medications prior
to the present illness. Three days after her surgery (with
prophylactic ampicillin/sulbactam administered as i.v.
bolus), the patient experienced acute epigastric pain with
vomiting and diarrhoea along with dyspnea that gradually
increased in severity. The patient had a temperature of
38.2°C, blood pressure of 90/60 mmHg, hearth rate of 120
beats/min, and respiratory frequency of 30 breaths/min.
Inspection of her thorax revealed decreased movement
of the chest wall, a hyperresonant percussion note, di-
minished fremitus and reduced breath sounds on the
right side. The abdominal examination showed distension,
guarding, and diffuse tenderness. The patient’s physical
signs and radiographic findings were compatible with
peritonitis and pneumothorax; the laboratory examination
revealed a leukocyte count of 2,100 cells/μL, with 84%
neutrophils and 3% eosinophils. A laparotomy revealed
purulent fluid throughout the abdominal cavity, which
was associated with fibrinous plaques covering most of
the abdominal viscera; these findings were the result of
a rectal perforation. A perforation closure was performed
and peritoneal toilets (a 9-day-toilet plan) were initiated.
The pneumothorax (Figure 1) was managed with a thora-
costomy tube drainage. The patient was admitted to
the intensive care unit (ICU) and began an empirical
treatment with piperacillin and tazobactam. On the day
of admission, an arterial blood analysis yielded PaO2 of
67 mmHg and SaO2 of 91.2% on ambient air. Non-invasive
ventilation was started under moderate sedation with
propofol. In the meantime, Enterococcus and Escherichia
coli were cultured from the peritoneal exudate. On the
seventh postoperative day, the patient’s clinical condition
worsened, with increasing intra-abdominal fibrinous
adhesions and paralytic ileus; the previous treatment
was discontinued and an empirical administration of
imipenem was begun on the conjecture of possible
resistant enterococci. On the tenth postoperative day,
Figure 1 High resolution computed tomography scan of the
chest. Large mantle pneumothorax at the level of the right middle
lobe, observed 3 days after hysterectomy.
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right side (Figure 2), with respiratory rate increased to 28
breaths/min; the pathological event was managed with a
thoracostomy tube drainage. Because the patient’s clinical
condition were worsened, imipenem was discontinued on
the twelfth day and substituted with tigecycline based on
the antibiotic-sensitivity results for Enterococcus faecium
isolated from the peritoneal toilet on the tenth postopera-
tive day. On the eighteenth postoperative day, the patient’s
respiratory distress increased (34 breaths/min and SaO2 ofFigure 2 Standard chest X-ray on the tenth postoperative day.
New mantle pneumothorax on the right side with diffuse interstitial
infiltrates in mid field of the left lung and left pleural effusion. No
cysts or bullae visible.88% with 6 L/min supplemental oxygen), her temperature
was 37.6°C, her hearth rate 110 beats/min and her
leukocyte count 19,400 cells/μL (neutrophils 86%; eo-
sinophils 2%). Computed tomography (CT) of the chest
revealed an abundant left-sided pleural effusion pressing
on the lower pulmonary lobe, and multiple areas of alveo-
lar infiltrates in the upper and middle right pulmonary
lobes. The serology (hepatitis B virus, hepatitis C virus,
human immunodeficiency virus, Cytomegalovirus, Chla-
mydia and Mycoplasma) eventually proved negative. Anti-
nuclear antibody, anti-neutrophil cytoplasmatic antibody
and rheumatoid factors were negative or non-specific. The
levels of immunoglobulin [Ig] G, IgA, IgM, complement
C3 and C4 were within the normal limits, and the IgE
concentration was 112 kU/L. The CD4+/CD8+ T lympho-
cytes ratio was 1.7; since this value is usually significantly
decreased in patients with various types of respiratory viral
infections, the presence of influenza virus and/or boca-
virus was not investigated.
The blood cultures for aerobic and anaerobic bacteria
remained sterile. No pneumocystis was detected by poly-
merase chain reaction. The patient was then empirically
treated withceftazidime and clarithromycin for atypical
pneumonia, on the basis on the radiographic findings.
Despite these measures, she did not improve and contin-
ued to have fever, with a temperature of approximately
37.5°C and mild leukocytosis. On the twenty-fifth post-
operative day, a chest CT scan demonstrated a left-sided
pneumothorax (Figure 3) with dense consolidations of
the left upper and middle pulmonary lobes along withFigure 3 High resolution computed tomography scan of the
chest. Extensive areas of air-space consolidations in both lungs and
bilateral alveolar opacities. Pneumothorax at the level of the left
lower lobe with bilateral pleural effusions.
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middle right pulmonary lobes. As the patient gradually
became more dyspneic and hypoxic, she was placed
under ventilation with continuous positive airway pressure.
Instead of previous antibiotics, rifampicin and moxifloxacin
were administered because of a positive test for Legionella,
which, however, was refuted by laboratory on the following
day. Because the patient’s respiratory failure further wors-
ened, the previous treatment was discontinued and empir-
ically substituted with three broad-spectrum antibiotics
(linezolid, meropenem and moxifloxacin). Eosinophilic
pneumonia was suspected when she showed no response
to antibiotics within the next 2 days. Bronchoscopy dem-
onstrated inflamed mucosa in both upper lungs with thick
secretions in both lower lungs, and many nucleated cells
(including 56% eosinophils) were detected in BAL fluid.
These findings unequivocally supported a diagnosis of AEP,
and parenteral methylprednisolone was initiated. Significant
recovery occurred within the next 24 h, so the antibiotics
were discontinued. The clinical symptoms further subsided
and the patient was successfully extubated within 2 days
after the initiation of steroids. The laboratory data and
chest radiology revealed marked improvement. After
20 days in the surgery department, the patient was dis-
charged (Figure 4) with a course of oral prednisone that
was tapered for 14 days. At 1 year following surgery, the
patient did not have any recurrence of her pulmonary
symptoms or infiltrates.Figure 4 Standard chest radiography performed on the day of
discharge from the hospital. Approximately one month after
corticosteroid therapy, a dramatic improvement of pneumonic
inflammation was observed with amelioration of bilateral infiltrates.
Absence of pleural effusions.Discussion
An effective starting point for commenting our case
might be the observation that our patient suffered from
three pneumothoraces during her recovery in the ICU.
Particularly, the first right-sided respiratory incident does
not appear to have been secondary to carbon dioxide
insufflation during the laparoscopy. Pneumothorax is a
well-known, although infrequent, complication of abdom-
inal laparoscopic surgery [15], with most pneumothoraces
diagnosed postoperatively using conventional chest X-rays.
In our case, the delayed onset of the pneumothorax on
the third postoperative day suggests that this patho-
logical event does not exhibit an etiopathogenesis due
to carbon dioxide insufflation, but should probably be
thought of as an adverse drug event associated with
propofol and/or midazolam [16] administration for indu-
cing the patient’s anaesthesia. Moreover, a characteristic
clinical sign that could indicate the occurrence of pneumo-
thorax during the laparoscopic surgery (i.e. alterations
in the electrocardiographic patterns) was absent in the
reported case; such a finding is a very sensitive indicator
of intra-operative pneumothorax [15]. The risk of recur-
rence after the first spontaneous pneumothorax has been
variably estimated [17] to be between 30% and 50% within
the first 2 years; after one recurrence the risk of additional
relapses within 3 years raises exponentially (to 62% after
the first recurrence and to 82% after the second one).
Although these intervals were not confirmed by other
studies, the average time to recurrence after the first
event has usually been spread over several years. The
three pathological conditions, in which air accumulated
within the thoracic cavity of our patient, thus appear
unrelated to the general pattern. In our case, all three
episodes occurred within three weeks, possibly due to
etiologies, such as exposures to inciting factors and
genetic predispositions, that should be examined in the
patient herself and in the internal or external environments
restricted to her recovery period in the ICU.
Doubts remain regarding the external factor that caused
AEP in our patient. Several studies have emphasized the
occurrence of drug-induced lung diseases [1]. Nonethe-
less, the clinician must have a high index of suspicion for
medications in the etiology of AEP, including those drugs
that have not been reported as causative agentsyet. Indi-
vidual genetic deficiencies in drug-metabolizing enzymes
may cause susceptibilities to certain pharmaceutical agents
that require detoxification, therefore these drug toxicities
may show unpredictable or idiosyncratic. In principle, all
chemical agents taken during the days or weeks preceding
the typical symptoms of AEP must be thoroughly investi-
gated. AEP often develops within a few days of drug initi-
ation. In theory, the only absolute proof that a drug is
responsible for eosinophilic pneumonia may be obtained
by linking its re-administration to ensuing relapses of the
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gerous. The regression of eosinophilic pneumonia, after
stopping the administration of a drug, is an indication
of its iatrogenic cause. However, corticosteroids are
often given concomitantly with drug withdrawals (as
also occurred in our patient) to accelerate the clinical
improvement, so the responsibility of a drug for AEP is
rarely established definitively.
Numerous and diverse broad-spectrum antibiotics were
administered for 23 days to our patient, because of peri-
tonitis and progression of lung infiltrations (the latter
showing no clinical improvement despite the pharma-
cological treatment). During her hospitalization in the
ICU, she was treated with not fewer than four drugs, that
have been reported to cause AEP or eosinophilia associ-
ated with parenchymal infiltrates: piperacillin/tazobactam
[18], clarithromycin [19], moxifloxacin (a fluoroquinolone
similar to levofloxacin [20]), and rifampicin [21]. In our
patient many drugs were used simultaneously or in close
sequence; thus, assigning toxicity to a specific agent was
difficult. Therefore, the authors hesitate to indicate one or
more of the various antibiotics as the cause of AEP and
admit their inability to reach a final decision on this point.
Perhaps there was a possible genetic predispositions to
the peculiar reactions of our patient’s pulmonary system.
Although, to our patient’s knowledge, no previous epi-
sodes of pneumothorax had occurred in herself or in her
relatives, the quick succession of all three episodes of
pneumothorax - crowded within one month instead of
years as for typical recurrences - strongly suggests a genetic
predisposition to distinctive reactions of the pulmonary
tissues, even though the underlying molecular defect
remains only presumed. Moreover, genetic factors have
been proposed as responsible for ordinary recurrences
when located on the controlateral side [22]; in our case, a
pattern of ipsilateral and controlateral respiratory incidents
was observed. Primary spontaneous pneumothoraces (PSPs)
may occur in patients with a variety of inherited disorders,
such as metabolic disorders (e.g. individual abnormalities
of the enzymes involved in biotransfomation) or connect-
ive tissue diseases [23]. Unfortunately, the latter could not
be diagnosed because our patient was discharged before
any consistent laboratory (e.g., electrophoretic analyses of
skin biopsies that reveal a lack of type III collagen or elas-
tin) or imaging (e.g., by electron microscopy) studies were
performed. Therefore, only tentative proposals are in
order. In our case, the precipitating cause for the first two
pneumothoraces could be ascribed to drugs, i.e. propofol
and/or midazolam [16], used for inducing anaesthesia
(first pneumothorax) or for increasing the patient’s com-
pliance during non-invasive ventilation (second pneumo-
thorax). Presuming that the structural or functional
proteins involved in the pathophysiology of pneumothorax
carry mutations that make a potential contributory causeto the disease, attention should be focused on the genetic
hyperreactivity of the pulmonary tissue rather than only
on eosinophilicchemoattractants (e.g., high concentrations
of IL-5) in the patient’s pleura or alveoli.
Additional anatomic considerations should be addressed.
By definition, PSP is not associated with an underlying
lung disease. However, this does not mean that there is
no hidden pathological process. It has become increasingly
apparent that PSP is associated with diffuse and often
bilateral abnormalities within the pleura; in other words, it
is not simply a disease caused by ruptured blebs/bullae,
but includes inflammation and pleural porosity, i.e. areas
of disrupted mesothelial cells in the visceral pleura that
are replaced by an elastofibrotic layer with increased
porosity, at level of which air leakage into the pleural
space is allowed. The high resolution CT images of our
patient’s chest, evaluated for the presence of possible
parenchymal abnormalities (e.g., emphysematous bullae
or cysts), were consistently negative. Therefore, in our
patient the causes at histological level of PSPs are likely
a combination of pleural porosities and inflammation.
Moreover, pulmonary tissues appear related to one an-
other, because they are derived from the endoderm and
mesoderm, which are two of the three primary germ
layers of the embryo. The endodermal lining of the lower
respiratory system gives rise to the pulmonary surface
epithelium, which in the terminal air sacs attenuates to
an extremely thin squamous epithelial layer, thus forming
the characteristic pulmonary alveoli. The lung connective
tissue and the visceral and parietal pleura (including
the blood and lymphatic vessels) are derived from the
surrounding splanchnic mesenchyme (i.e., from the meso-
derm). Thus, it is not surprising that the pathophysiology
of PSP is coupled with inflammatory changes of the lungs
and pleural cavity [24]. This structural/functional com-
munication between the tissues of the pleura and lungs
(based on the common embryonic origin of their connect-
ive tissue) is also expected to be reciprocal.
These latter remarks are confirmed and strengthened
by comparing the pathological occurrences of our patient
with cases of AEP/pneumothorax comorbidity, that are
documented in the biomedical literature. A PubMed search,
conducted using the search terms acute eosinophilic pneu-
monia and pneumothorax, resulted in 37 citations, but
only in two studies [25,26] a true combination of these
pathological events was established. In one case, a 55-
year-old man [25] (i) developed the AEP symptoms three
weeks after the beginning of treatment with the anti-
depressant trimipramine and (ii) suffered from a spontan-
eous pneumothorax fifteen days after this episode; when
trimipramine was discontinued, the characteristic features
of respiratory failure quickly subsided and the lung infil-
trate disappeared. In the other case [26], a 14-month-old
girl met the criteria for the diagnosis of idiophatic AEP,
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by high-resolution computed tomography; in this case,
such a disease cluster possibly occurred simultaneously.
Areas of significant pulmonary abnormalities, such as
blebs and bullae, were not described in these studies;
therefore, in both cases the anatomic and histological
state of pleural and lung tissues is comparable to that
of our patient. In addition to this structural likeness,
the pulmonary system of all patients taken here into
account (i.e. that investigated in this work, as well as in
[25] and in [26]) appears to share a common suscepti-
bility to different agents, such as certain drugs and/or
allergens, and to respond to these elements in a similar
way, even though with different intensity (e.g., three
pneumothoracesversus only one air leak). If it is how
things stand, it follows that (i) PSP can precede [this
work], or be simultaneous to [this work, and Ref. [26] or
follows [25] AEP, and (ii) the attainment of comorbidity
within one patient always occurs in a very short time (a
few days or weeks, at latest). These data seem to imply
that the pleura and lung form a functional continuum
possibly through the connective tissue, within which
elemental signals of inflammation migrate from a com-
partment (pleura or lung) to the other and vice versa.
On the whole, these considerations strongly suggest
that all pathological events observed in our patient dur-
ing her hospitalization (i.e., three pneumothoraces and
AEP), reasonably reminiscent of analogous cases found
in literature, are in line with the presence of a rare genetic
predisposition at the molecular level of certain structures,
possibly located into the connective tissue (see below)
within her respiratory system.
A few conjectures address objections to the genetic
influence on AEP. The following question arises: if some
of the underlying etiologies of AEP are genetic, then
why is the absence of recurrence so characteristic of
this disease after corticosteroid treatment? Since the
genetic features of the lung-tissue responsiveness can
be suppressed but never destroyed, the abnormal reactivity
is expected to recur whenever the inciting stimulus
returns. However, several cases of AEP in which tobacco
smoking was suspected to be the cause have shown no
recurrence despite the reinitiation of smoking. These
cases have been explained by the development of toler-
ance to tobacco [27] (however, without putting forward
any sound mechanism), because the provocation tests
(i.e., cigarette-smoking challenge tests designed to es-
tablish a causative link between AEP and the volatile
constituents of cigarette smoke) were usually not asso-
ciated with recurrent symptoms. By contrast, in drug-
induced AEP, clinical improvement occurs with cessation
of the offending agent, but symptoms usually recur after
renewed administration of the medication. What then
is the pathophysiological basis for interpreting thesephenomenological differences between tobacco-induced
and drug-stimulated AEP?
Alveolar and bronchial epithelial cells are injured through
inhalation (e.g., by tobacco smoke or air-borne dust) or
through the vascular system (e.g., by the medications).
In AEP, the pathological changes at the epithelial level
are potentially reversible. Once the inflammatory response
has been suppressed by steroid treatment, an immediate
tissue repair begins, involving the migration of the so-
called type II epithelial cells adjacent to the area of damage
(i.e., the stem cells of the alveolar epithelium) and leading
to the complete restoration of the normal epithelial barrier
function [28] i.e., the lung’s first line of defense against
the external environment. In patients who have recovered
from AEP caused by tobacco use, the resumption of smok-
ing appears to elicit an unresponsive state [28], which may
develop at the immune cells level in the lung parenchyma.
Notably, specialized antigen-presenting cells (APCs), spe-
cifically the subset of dendritic cells (DCs), have emerged
as central players in the immunological balance of the
airways [29]. DCs include a heterogeneous family of
professional APCs that are involved in the initiation of
both immunity and immunological tolerance [30,31].
Compared with other cell types involved in the immune
response, the tolerogenic DC (tDC) subset presents anti-
gens that are captured in the “absence of microbial prod-
ucts or inflammatory mediators”, as typically occurs after
the treatment with corticosteroids (e.g., in AEP cases) [32].
In particular, the resumption of smoking induces the
following behavior at histological level: (i) migrating DCs
interact with the resident alveolar cells and continually
assess whether inhaled material should be confronted
with an active immune response or whether homeostatic
tolerance should be maintained (thus retaining an efficient
low-alert surveillance mechanism that avoids an unneces-
sary inflammatory response), and (ii) the stimulation of
survival signals from the alveolar epithelium locally en-
hances DCs survival.
As mentioned above, AEP is an adverse reaction only
to abrupt modifications of smoking habits (particularly,
the initiation of tobacco use or the increase in the daily
smoking dose). In such cases, the alveolar cells are over-
whelmed by copious amounts of tobacco-related toxic
substances that cause vast injuries to the continuous
single-cell layer of the epithelium (through the suppres-
sion of proliferation, apoptosis, or necrosis, depending on
the concentration of volatile components from the ciga-
rettes); consequently, extensive portions of the underlying
mesodermally-derived connective tissue are exposed. Ac-
cording to this model, we hypothesize that this connective
tissue is the target of the inciting factor that provokes
AEP. Healthy individuals become susceptible to AEP
during periods of marked variations in their smoking
habits, because of the loss of alveolar epithelial cells
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the epithelial repair process; consequently, irritants from
tobacco smoke can access extensive portions of the
connective tissue. On the contrary, there is no physical
barrier against the transport of drugs through the blood
to the target tissue; therefore, the suspension or re-
administration of an offending drug determines the im-
provement or relapse of the disease. Thus, the failure
to relapse after a patient recovers from medication-
induced AEP is strictly dependent on the complete ces-
sation of any drug considered to be the most probable
cause of the AEP episode; therefore, no tolerance to
medications is expected.Conclusions
Our patient discloses the first observational collection
of clinical data supporting the hypothesis that the med-
ications used to treat overt disorders (e.g., peritonitis or
lung infiltrations, as in our patient) or the exposure to
tobacco smoke (but also fine, airborne sand or dust, as
in the so-called idiopathic AEP) can all contribute to the
development of non-infectious AEP, but “only in rare,
genetically predisposed” subjects with mutations probably
located within the connective tissue of the lung. An emer-
ging consensus suggests that the described pattern of
causative cofactors (i.e., the genetic predispositions or
attributes and the environmental/external exposures to
pathogenetic inducers) is common to certain lung diseases,
such as asthma, chronic obstructive pulmonary disease
and pulmonary fibrosis. We propose the addition of AEP
to this list.
The genomic age is upon us. Therefore, if the mecha-
nisms of the recruitment of inflammatory cells (such as
eosinophils) in the airways are governed by the genetic
characteristic of the pulmonary tissues, then genomic
information in the diagnosis and treatment of AEP would
seem nowadays necessary. In fact, physicians in some
disciplines have already begun to use genetic profiles in
their general practices, and in future many patients will
most likely be analyzed for sequence information that
outlines the genetic variations within their entire genomes.
The promise of personalized medicine is a clinical reality.
However, in our opinion, the use of genetic information to
treat AEP patients would provide negligible profit because
of the following factors: (i) the potential assistance in
predicting the individual risk for AEP can fairly be
disregarded because the prognosis is generally good; if
however AEP is not considered in the differential diagno-
sis of respiratory failure, causing the disease to remain
unrecognized with a consequent failure to administer
corticosteroids to the patient, then death may occur, and
(ii) full responsiveness to corticosteroids routinely occurs
and relapses has never been described. Therefore, cortico-steroids remain the mainstay of therapy for AEP, and there
is no need for a personalized therapy.
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